Twist Bioscience (TWST) to Release Earnings on Monday

Twist Bioscience (NASDAQ:TWSTGet Free Report) will announce its earnings results before the market opens on Monday, November 18th. Analysts expect the company to announce earnings of ($0.73) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Twist Bioscience Price Performance

Shares of NASDAQ:TWST opened at $36.89 on Friday. Twist Bioscience has a fifty-two week low of $18.80 and a fifty-two week high of $60.90. The business has a 50-day moving average of $43.90 and a two-hundred day moving average of $45.91. The stock has a market capitalization of $2.16 billion, a P/E ratio of -9.66 and a beta of 1.78.

Analyst Ratings Changes

TWST has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. lifted their price objective on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. Robert W. Baird boosted their price target on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research note on Monday, August 5th. Leerink Partners boosted their price target on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. Evercore ISI boosted their price target on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Finally, Barclays lowered their price target on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.22.

Get Our Latest Report on TWST

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, SVP Paula Green sold 1,057 shares of the company’s stock in a transaction on Monday, November 4th. The stock was sold at an average price of $41.56, for a total transaction of $43,928.92. Following the transaction, the senior vice president now owns 121,013 shares of the company’s stock, valued at approximately $5,029,300.28. This represents a 0.87 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Emily M. Leproust sold 1,730 shares of the company’s stock in a transaction on Friday, September 20th. The stock was sold at an average price of $46.94, for a total value of $81,206.20. Following the transaction, the chief executive officer now directly owns 495,523 shares in the company, valued at approximately $23,259,849.62. This represents a 0.35 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 98,118 shares of company stock valued at $4,391,151 in the last three months. 3.92% of the stock is owned by corporate insiders.

About Twist Bioscience

(Get Free Report)

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

Further Reading

Earnings History for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.